Natera stung for $57m in prenatal screening clash

Dispute centres on genetic prenatal screening methodology | Ravgen’s $57 million award “significantly less” than the $410 million sought by Ravgen | Natera plans to appeal.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotech

Masimo keeps $634m smartwatch award and moves to appeal

21 July 2026 Now a Danaher subsidiary, the company is contesting a number of orders after a California court finalised several aspects of the high-profile dispute.

Biotech

Arbutus takes Comirnaty LNP patent fight to Canada and UPC

20 July 2026 The biotech company has launched a trio of lawsuits against two vaccine makers, while announcing receipt of a $178 million sum from Moderna under a previous deal.

Biotech

Illumina ordered to recall products after German patent ruling

16 July 2026 A Munich court ruled that Illumina infringed a rival’s DNA sequencing patents, handing the challenger an early victory in a dispute that is playing out across Europe and the US.

More features

Masimo keeps $634m smartwatch award and moves to appeal

Arbutus takes Comirnaty LNP patent fight to Canada and UPC

Why is 2026 already a record year for M&A activity?

Illumina ordered to recall products after German patent ruling

Goodwin launches San Diego office with senior life sciences hire

Sanofi launches mRNA vaccine lawsuits at Moderna and Pfizer

UK-Switzerland strike trade deal with first-of-its-kind pharma rules

IP Federation elects Philips licensing leader as new president

Natera stung for $57m in prenatal screening clash

More on this story

Editor's picks

Editor's picks

More features